The pandemic has irrevocably upended the state of patient care in the U.S., with many of these changes likely to persist indefinitely. Already a growing sector of the healthcare industry, digital therapeutics and remote-care technology quickly became buzz words within the industry as millions of practices, physicians, and patients engaged with the technology. Broader familiarity with and support for telehealth and digital healthcare tools among physicians and patients has been a boon for digital therapeutic manufacturers eager to extoll the virtue and value of these technologies.
However, in addition to providing opportunities for innovation, the pandemic has exposed vulnerabilities and bare spots within our healthcare system. Mental health professionals, while already understaffed to treat the current patient population, are expected to see a massive rise in number of patients and services requested in the wake of COVID-19. Digital therapeutics show promise in addressing these demands, but the extent of their effectiveness will depend entirely on their adoption and level of access provided by insurers. Payers are adamant about their internal evaluation frameworks for digital therapeutics and it is essential that all manufacturers be mindful of these throughout the commercial process in order to ensure the successful launch of their digital solution.
Join us for a complimentary webinar as we reveal results from new Ipsos research with national/regional payers, to help manufacturers refine their digital health offers. During this session, expect to hear more about how promoting the long-term benefits of their products to the overall healthcare system in terms of resources and expenses saved will result therapeutic success.
Robert Rava, Senior Vice President, Health Custom
Will Knopp, Account Manager, Health CS&F